

University of Groningen

Early effects of brain death on kidney injury and outcome after transplantation

Nijboer, Wijmtje Nikeline

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:
2010

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Nijboer, W. N. (2010). *Early effects of brain death on kidney injury and outcome after transplantation*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).


The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

CHAPTER



INFLAMMATORY ANGIOPOIETIN RESPONSE IN DECEASED BRAIN DEAD DONORS

Lyan G. Koudstaal, Willemijn N. Nijboer, Johannes G. Burgerhof, Jaap J. Homan van der Heide,
Vincent B. Nieuwenhuijs, Maarten W. Nijsten, Harry van Goor, Rutger J. Ploeg, Henri G.D. Leuvenink

- ABSTRACT -

Background:

Kidneys retrieved from deceased brain dead (DBD) donors show inferior function compared to living donors. Bacterial translocation and endotoxemia as well as inflammation are frequent in DBD donors. Recently it was shown that in endotoxic patients the angiopoietin levels are influenced. We hypothesized that the anti-inflammatory protein angiopoietin-1 (Ang-1) and the pro-inflammatory Angiopoietin 2 (Ang-2) are shifted towards inflammation in DBD donors compared to living donors. Therefore, we studied serum vascular endothelial growth factor (VEGF), Ang-1 and Ang-2 in DBD donors using living kidney donors as controls. Lipopolysaccharide Binding Protein (LBP) was used to quantify endotoxemia.

Methods:

Serum was collected just after confirmation of brain death diagnosis (T0) and immediately prior to organ recovery (T1) from 30 consecutive DBD donors. Twenty living donors were asked informed consent for two blood samples, obtained at the beginning of the operation and immediately prior to retrieval of the donor kidney.

Results:

DBD donors had higher median serum LBP, VEGF and Ang-2 levels compared to living donors. Higher Ang-1 levels were observed just after brain death diagnosis compared to living donors. Serum levels of LBP and Ang-2 were correlated with a Spearman's ρ of 0.6. Importantly, serum Ang-2 levels in the DBD donor predicted the chance on rejection in the first year after kidney transplantation with an odds ratio at T0 1.38 and at T1 1.50 ($P < 0.05$).

Conclusions:

The angiopoietin balance in brain dead donors is modulated progressively towards inflammation during the period of brain death prior to organ recovery.

- INTRODUCTION -

Organs recovered from heart beating deceased brain dead (DBD) donors show inferior organ function and a higher rate of acute rejection compared to those obtained from living donors (1-4). Both in humans and in experimental models, brain death induces a progressive inflammatory response in potential donor organs such as kidney, liver and intestine (5-7). This response coincides with systemic higher levels of circulating cytokines including interleukin (IL)-1, IL-6, tumor necrosis factor alpha, vascular endothelial growth factor, and macrophage chemoattractant protein-1 (8-10). The exact mechanism responsible for these pro-inflammatory changes and their detrimental effect on transplant outcome are yet unknown.

The intestine is considered to be a crucial player in the development of distant organ injury. In several conditions, such as severe burns, brain injury, acute pancreatitis and Acute Respiratory Distress Syndrome (ARDS), enhanced intestinal permeability is associated with distant organ injury (11-15). Several human studies have provided evidence that DBD donors have a higher endotoxin load. Bacterial translocation and elevated endotoxin levels are also frequent in DBD donors (16). Almost half of the donors have positive cultures of the ileocecal lymph node (17).

Recently, a link between endotoxemia and Angiotensin 1 (Ang-1) and Angiotensin 2 (Ang-2) has been established. In humans, LPS is a triggering factor for Ang-2 release (18). Ang-1 and Ang-2 both are regulatory proteins which play an important role in vascular inflammation. The angiotensin-Tie ligand-receptor system is crucial in regulating vascular integrity and quiescence (19). Ang-1 dampens the inflammatory response while Ang-2 boosts it (20).

Ang-1 has the ability to seal the vasculature, act as an anti-inflammatory agent, protect against cardiac allograft arteriosclerosis and renal fibrosis, and promote wound healing (21-24). Ang-2 is associated with an increased morbidity and mortality during sepsis. A model has been reported which indicates that a balanced Ang-1/Ang-2 ratio determines the functional status of the vasculature (25). It has also been shown that *in vivo* endotoxemia triggers functional inhibition of the angiotensin pathway by reducing Ang-1 expression and inducing Ang-2 levels and that this response may contribute to enhanced vascular leakage during sepsis (26).

We hypothesized that in heart beating brain dead donors the inflammatory proteins Ang-1 and Ang-2 are shifted towards inflammation. Living kidney donors were used for comparison as controls. Further, we questioned whether the Ang-1 and Ang-2 status in the DBD donor can be used as a prognostic tool to predict renal function after transplantation including delayed graft function (DGF) and rejection. Therefore, we studied serum Ang-1 and Ang-2 in 30 DBD donors and 20 living kidney donors and linked the results to clinical kidney transplant outcome. We studied serum lipopolysaccharide Binding Protein (LBP) as a quantification of endotoxemia in kidney donors serum and vascular endothelial growth factor (VEGF), because it has been shown Ang-2 primes the endothelium to respond to VEGF (27-33).

-METHODS -

Patients and serum samples

Serum samples were prospectively, consecutively collected during organ procurement procedures from a series of heart beating DBD donors, from 2004 through 2007. Selection criteria were donor age <65y and a cold ischemia time <30h. All donors were declared brain dead on the intensive care. All samples were collected after declaration of brain death, according to the Dutch Transplantation Law. Baseline samples were collected just after brain death diagnosis (T0). A second sample (T1) was obtained prior to organ recovery just before wash-out and preservation. Due to logistic reasons, at T0 in four DBD donors no serum could be obtained. Twenty living kidney donors were asked informed consent for two blood samples: a baseline sample (T0) just before the donor operation (T0) and a second sample (T1) at the time of kidney recovery during the donor operation just prior to retrieval. All samples were kept on ice, centrifuged for 20 minutes at 1500 x g and stored at -80°C until analysis. Clinical donor variables were recorded and one year-follow up of kidney function after transplantation was received from recipient hospitals. As the end points for clinical outcome were used: Delayed graft function (DGF), defined as the need for dialysis in the first week after transplantation; rejection, defined as biopsy proven rejection in the first year and serum creatinine in the recipient on day 14 after transplantation. All grades of interstitial and vascular rejection were included. Borderline rejection was excluded. Biopsies were scored during routine clinical practice by a blinded pathologist according to the BANFF classification.

Serum Lipopolysaccharide Binding Protein (LBP)

To evaluate LBP in serum samples from all patients included in the study an enzyme-linked immunosorbent assay (ELISA) test kit (HyCult Biotechnology, Uden, The Netherlands) for Human Lipopolysaccharide Binding Protein (LBP) was used, according to the manufacturer's instructions, with an upper reference value for healthy individuals of 10 µg/ml. All samples were tested in duplicate and read at 450 nm, in a microplate reader (Victor3, 1420 multilabel counter, Perkin Elmer).

Serum Vascular endothelial growth factor (VEGF)

To determine VEGF levels, serum samples were measured using a multiplex bead sandwich immunoassay (Biosource, Invitrogen, Carlsbad, CA) which was analyzed using a Luminex 100 instrument (Luminex, Austin, TX).

Serum angiotensin 1 and 2

Human Ang-1 and Ang-2 enzyme-linked immunoassay (ELISA) test kits (R&D systems, Minneapolis, USA) were used according to the manufacturer's instructions, to evaluate Ang-1 and Ang-2 in serum samples from all patients included in this study. The upper reference value in healthy individuals for ang-1 is 6 ng/ml and ang-2 is 2.5 ng/ml (34). All samples were tested in duplicate and read at 450 nm using a microplate reader (Victor3, 1420 multi-label counter, Perkin Elmer).

Statistical methods

Statistical analysis was performed using the computer program SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Results are expressed as median and 25 and 75 percentiles. Statistical comparisons between groups were performed using a T-test if data had a normal distribution; otherwise groups were compared using the Mann-Whitney U test. Dichotomous variables were compared using Fisher's test. The association between LBP, VEGF, ang-1 and ang-2 was tested with Spearman's rho. For linear regression a normal distribution of the residues was checked using a normal probability plot. Multivariate stepwise logistic regression with the log likelihood test was used for the dichotomous variables, DGF and rejection. For serum creatinine in the recipient on day 14 after transplantation multivariate linear regression was used. In all models as covariates donor age, HLA-mismatches, sex, cold ischemia time were tested. All differences were considered to be significant at $P < 0.05$.

-RESULTS -

In this study 30 DBD donors and 20 living renal donors were included; all kidneys obtained from these donors were transplanted. The median time between T0, declaration of brain death and T1, at the time of kidney recovery was 11 hours (10-13). The cause of death was a cerebrovascular accident (CVA) in 19 donors and 11 donors with a trauma capitis or other cause. The occurrence of DGF and serum creatinine after 14 days was recorded for all patients; however occurrence of rejection in the first year was analyzed in 48 patients. Ten DBD donors experienced DGF compared to one in the living donors and six DBD donors experienced rejection compared to three living donors ($P < 0.05$). One patient experienced graft loss four weeks post-transplant due to mycotic aneurysm, two patients died with a functioning graft and two patients were referred to non-participating hospitals. Donor characteristics are shown in Table 1.

Table 1 Characteristics of DBD and Living Donors and Kidney Recipients


	DBD Donors	Living donors	P-value
Gender (M:F) ^c	10:20	7:13	0.903
Age (years) ^b	49 (42-57)	50 (44-58)	0.246
Cause of death			
CVA	19		
Trauma/Other	11		
Serum creatinine T0 (μmol/L) ^a	60 (49-87)	64 (60-70)	0.782
Serum creatinine T1 (μmol/L) ^a	57 (48-72)	55-68)	0.357
Post-transplant Parameters			
Cold Ischemia Time (hours) ^a	198 (15-23)	3 (2-3)	0.001
HLA mismatch ^a	2 (2-3)	3 (2-4)	0.01
First transplant ^a	28/30	20/20	0.0001
Serum Creatinine day 14 (μmol/L) ^a	166 (114-556)	133 (116-185)	0.111
Delayed Graft Function ^c	10	1	0.033
Rejection ^c	6	3	0.716
Immunosuppressive Treatment			
Prednisolon/Mycophenolate mofetil/Cyclosporine	24	20	
Prednisolon/Mycophenolate mofetil/Tacrolimus	2	0	
Prednisolon/Cyclosporine/ FTY720	1	0	
Prednisolon/Mycophenolate mofetil/Rapamycin	1	0	
Antithymocyte globulin	2	2	
Daclizumab	4	9	
Basiliximab	3	2	
Unknown	2	0	

Mann Whitney U test ^a; Student's T-test ^b; Fisher's test ^c; Results of age and serum creatinine are expressed as median and 25 and 75 percentiles.

In the serum of DBD donors we found significantly higher LBP, VEGF, Ang-1 and Ang-2 levels at T0 ($P < 0.001$) and higher LBP, VEGF and Ang-2 levels at T1 ($P < 0.001$). Interestingly, the Ang-1 levels decreased significantly during the brain death period ($P < 0.001$). In DBD donors at T1 the Ang-1/Ang-2 ratio was decreased compared to living donors ($P < 0.001$). In DBD donors the Ang-1/Ang-2 ratio decreased from T0 to T1 (Figure 1) ($P < 0.001$).

Figure 1


Dot plots of Lipopolysaccharide Binding Protein a, Vascular Endothelial Growth Factor b, Angiopoietin-1 c, Angiopoietin-2 d and ratio Ang1/Ang2. Medians are shown. Baseline samples were collected just after brain death diagnosis (T0). A second sample (T1) was obtained during organ recovery just prior to wash-out and preservation.



In DBD donors we observed high Ang-1 levels at T0 in all donors who died from a stroke (n=19). At T0 median Ang-1 levels were 24 (17-31) ng/ml in donors who died from a CVA compared to 9 (6-14) ng/ml in donors with another cause of death (P<0.05). These medians did not differ anymore during organ recovery. In donors respectively a CVA or with another cause of death, Ang-1 levels were at T1 6(3-8) ng/ml vs. 8 (5-10) ng/ml (NS). We also studied the association between Ang-1 and LBP and the association between Ang-2 and LBP. We found an association at T0 of LBP with Ang-2 with a Spearman's ρ of 0.622 (P<0.001) and at T1 of 0.603 (P<0.001) (Figure 2).

Figure 2


Dot plots correlation between Serum Lipopolysaccharide Binding Protein and Serum angiopoietin 2 in deceased brain dead donors (DBD) at T0, baseline just after brain death diagnosis (a) and T1 during organ recovery just prior to wash-out and preservation (b).



To evaluate whether levels of Ang-1, Ang-2 or the Ang-1/Ang-2 ratio in the DBD donor group had an independent effect on outcome after transplantation linear and logistic step-wise multivariate regression models were built. DGF, rejection and serum creatinine on day 14 following transplantation were studied. As covariates donor age, HLA-mismatches, sex, cold ischemia time were tested. Only donor age did predict DGF, with an OR of 1.1 ($P < 0.05$). Elevated Ang-2 levels were associated with an increased risk of rejection with an odds ratio at T0 1.377 and at T1 1.499 ($P < 0.05$). In contrast, donor serum creatinine did not predict kidney outcome after transplantation. DGF and serum creatinine on day 14 were not predicted by LBP, VEGF, Ang-1, Ang-2, or the Ang-1/Ang-2 ratio. ROC analyses are presented in Figure 3 to evaluate the prognostic effect of serum Ang-2 on rejection in the first year after transplantation. The area under the curve for both time point was 0.8 ($P < 0.05$). With an angiotensin value of 4.5 ng/ml, the sensitivity is 0.8 with a false negative rate of 0.2.

Figure 3

ROC analyses of angiotensin-2 to predict rejection in the first year after transplantation.



-DISCUSSION -

The cardinal finding of this study is the modulated angiopoietin balance in brain dead donors towards pro-inflammatory activation. Just after the diagnosis of brain death and prior to organ recovery, we found higher serum Ang-2 levels compared with living donors. Interestingly, we also observed higher Ang-1 levels just after brain death diagnosis compared to living donors. These Ang-1 levels decreased during the period of brain death until the moment of organ recovery to levels comparable with living donors. Similarly, during the brain dead period the ratio of Ang-1/Ang-2 decreased significantly, shifting to pro-inflammatory activation. In addition, serum Ang-2 levels in the DBD donor predicted the chance of rejection in the recipient. The area under the curve of the ROC analysis, was 0.8, showing a good discriminating potential of Ang-2. Therefore, among the other prognostic factors, Ang-2 can add relevant information for clinical decision-making to determine whether a kidney will be suitable for transplantation. Based only on this study, it is too premature to draw definite conclusion. Further research is needed to evaluate Ang-2 prognostic value.

In this study we observed an enhanced endotoxin load as evidenced by the elevated serum LBP levels in DBD organ donors in contrast with living organ donors. This is in accordance with the observation that bacterial translocation is common in organ donors (35;36). LBP was shown to be a sensitive marker of prolonged endotoxin exposure (37), and our analysis revealed that prolonged exposure to endotoxins was present in the majority of heart beating DBD donors.

Serum Ang-2 and VEGF are markedly elevated in several conditions such as sepsis and trauma (38;39). Angiopoietins play also a role in various kidney diseases (40). In trauma patients with severe injury and systemic hypoperfusion, Ang-2 is released within 30 minutes after trauma and high levels of Ang-2 were associated with an activated endothelium, coagulation abnormalities, complement activation, and worse clinical outcome (41). In addition, in patients with acute lung injury (ALI) and ARDS high levels of circulating Ang-2 are associated with pulmonary permeability oedema, occurrence and the severity of ALI/ARDS as well as with mortality (42;43). Furthermore, kidney grafts from living unrelated donors have high survival rates, despite a higher degree of HLA mismatching than is found in deceased grafts (44). The inferior survival of deceased donation cannot be attributed to differences in immunogenicity alone. Even when corrected for donor variables such as donor age, gender, race, terminal serum creatinine, shorter cold-ischemia times, cerebrovascular accident as the cause of death, and history of hypertension organs recovered from deceased donors show inferior outcome (45;46). The observed systemic inflammatory state and extend of injury in DBD donors is thought to induce worse outcome (47-51). The modulated inflammatory Angiopoietin response is in line with these observations.

In DBD donors the Ang-1/Ang-2 ratio is decreased and progressively shifted towards pro-inflammatory activation. Intervening in the Ang-1/Ang-2 balance may therefore be of therapeutic value to improve outcome after transplantation when kidneys from heart beating DBD donors are used. Ang-2 neutralizing reagents have been developed as anti-angiogenic

tumor drugs (52) and could also be used to decrease the pro-inflammatory status of the donor. Increasing the Ang-1 concentration to restore the balance has a potent anti-inflammatory potential in animal models, although Ang-1 therapies have also shown side effects like pulmonary hypertension (53;54).

Interestingly, hypertensive patients have higher levels of Ang-1, even without target organ damage (55). In DBD donors we observed high Ang-1 levels at T0 in all donors who died from a stroke (n=19). The elevated levels of Ang-1 in donors who died from a stroke direct after declaration of brain dead, but not just before organ recovery, may reflect a protective response or reflect chronic vascular dysfunction in stroke patients.

We also found a strong association between LBP and Ang-2 levels at both time points. The higher Ang-2 levels, combined with the lower Ang-1 levels just before organ recovery, are in accordance with triggering of Ang-2 by administration of LPS to healthy volunteers and with the observation in mice, that endotoxemia triggers functional inhibition of the Ang-1 pathway in vivo by reducing vng-1 expression and inducing Ang-2 (56;57).

We conclude that the angiotensin balance in brain dead donors is modulated progressively towards pro-inflammatory activation. Angiotensin-2 could be a valuable marker to predict the quality of the renal graft as early as in the donor.

References

1. Weiss S, Kotsch K, Francuski M, Reutzel-Selke A, Mantouvalou L, Klemz R, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. *Am J Transplant* 2007 Jun;7(6):1584-93.
2. Sanchez-Fructuoso A, Naranjo GP, Calvo RN, Ridao N, Naranjo GP, Conesa J, et al. Effect of the brain-death process on acute rejection in renal transplantation. *Transplant Proc* 2007 Sep;39(7):2214-6.
3. Pratschke J, Neuhaus P, Tullius SG. What can be learned from brain-death models? *Transpl Int* 2005 Jan;18(1):15-21.
4. Bos EM, Leuvenink HG, van Goor H, Ploeg RJ. Kidney grafts from brain dead donors: Inferior quality or opportunity for improvement? *Kidney Int* 2007 Oct;72(7):797-805.
5. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. *Transplantation* 1998 Jun 27;65(12):1533-42.
6. van Der Hoeven JA, Molema G, Ter Horst GJ, Freund RL, Wiersema J, van SR, et al. Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. *Kidney Int* 2003 Nov;64(5):1874-82.
7. Koudstaal LG, 't Hart NA, van den Berg A., Olinga P, van GH, Ploeg RJ, et al. Brain death causes structural and inflammatory changes in donor intestine. *Transplant Proc* 2005 Jan;37(1):448-9.
8. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. *Transplantation* 1998 Jun 27;65(12):1533-42.
9. Lopau K, Mark J, Schramm L, Heidbreder E, Wanner C. Hormonal changes in brain death and immune activation in the donor. *Transpl Int* 2000;13 Suppl 1:S282-S285.
10. Kusaka M, Pratschke J, Wilhelm MJ, Ziai F, Zandi-Nejad K, Mackenzie HS, et al. Activation of inflammatory mediators in rat renal isografts by donor brain death. *Transplantation* 2000 Feb 15;69(3):405-10.
11. Sambol JT, Xu DZ, Adams CA, Magnotti LJ, Deitch EA. Mesenteric lymph duct ligation provides long term protection against hemorrhagic shock-induced lung injury. *Shock* 2000 Sep;14(3):416-9.
12. Hang CH, Shi JX, Li JS, Wu W, Yin HX. Alterations of intestinal mucosa structure and barrier function following traumatic brain injury in rats. *World J Gastroenterol* 2003 Dec;9(12):2776-81.
13. Deitch EA, Shi HP, Lu Q, Feketeova E, Skurnick J, Xu DZ. Mesenteric lymph from burned rats induces endothelial cell injury and activates neutrophils. *Crit Care Med* 2004 Feb;32(2):533-8.
14. Fang CW, Yao YM, Zhai HX, Yu Y, Wu Y, Lu LR, et al. Tissue lipopolysaccharide-binding protein expression in rats after thermal injury: potential role of TNF-alpha. *Burns* 2004 May;30(3):225-31.
15. Liu H, Li W, Wang X, Li J, Yu W. Early gut mucosal dysfunction in patients with acute pancreatitis. *Pancreas* 2008 Mar;36(2):192-6.
16. van Goor H., Rosman C, Grond J, Kooi K, Wubbels GH, Bleichrodt RP. Translocation of bacteria and endotoxin in organ donors. *Arch Surg* 1994 Oct;129(10):1063-6.
17. Kane TD, Johnson SR, Alexander JW, Craycraft TK. Bacterial translocation in organ donors: clinical observations and potential risk factors. *Clin Transplant* 1997 Aug;11(4):271-4.
18. Kumpers P, van MM, David S, Molema G, Bijzet J, Lukasz A, et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. *Crit Care* 2009 May 5;13(3):R64.
19. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. *Trends Immunol* 2006 Dec;27(12):552-8.

20. Imhof BA, Urrand-Lions M. Angiogenesis and inflammation face off. *Nat Med* 2006 Feb;12(2):171-2.
21. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. *Nat Med* 2000 Apr;6(4):460-3.
22. Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. *Circulation* 2003 Mar 11;107(9):1308-14.
23. Cho CH, Sung HK, Kim KT, Cheon HG, Oh GT, Hong HJ, et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. *Proc Natl Acad Sci U S A* 2006 Mar 28;103(13):4946-51.
24. Kim W, Moon SO, Lee SY, Jang KY, Cho CH, Koh GY, et al. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. *J Am Soc Nephrol* 2006 Sep;17(9):2474-83.
25. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. *Trends Immunol* 2006 Dec;27(12):552-8.
26. Mofarrah M, Nohu T, Qureshi S, Guillot L, Mayaki D, Hussain SN. Regulation of angiopoietin expression by bacterial lipopolysaccharide. *Am J Physiol Lung Cell Mol Physiol* 2008 May;294(5):L955-L963.
27. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. *J Exp Med* 1994 Sep 1;180(3):1025-35.
28. Jerala R. Structural biology of the LPS recognition. *Int J Med Microbiol* 2007 Sep;297(5):353-63.
29. Vollmer T, Piper C, Kleesiek K, Dreier J. Lipopolysaccharide-Binding Protein: A New Biomarker for Infectious Endocarditis? *Clin Chem* 2008 Oct 2.
30. Sakr Y, Burgett U, Nacul FE, Reinhart K, Brunkhorst F. Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? *Crit Care Med* 2008 Jul;36(7):2014-22.
31. Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. *Intensive Care Med* 2007 Jun;33(6):1025-32.
32. Meisner M. Biomarkers of sepsis: clinically useful? *Curr Opin Crit Care* 2005 Oct;11(5):473-80.
33. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. *Trends Immunol* 2006 Dec;27(12):552-8.
34. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. *Atherosclerosis* 2005 May;180(1):113-8.
35. van Goor H., Rosman C, Grond J, Kooi K, Wubbels GH, Bleichrodt RP. Translocation of bacteria and endotoxin in organ donors. *Arch Surg* 1994 Oct;129(10):1063-6.
36. Kane TD, Johnson SR, Alexander JW, Craycraft TK. Bacterial translocation in organ donors: clinical observations and potential risk factors. *Clin Transplant* 1997 Aug;11(4):271-4.
37. Albillos A, de la HA, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. *Hepatology* 2003 Jan;37(1):208-17.
38. Ganter MT, Cohen MJ, Brohi K, Chesebro BB, Staudenmayer KL, Rahn P, et al. Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? *Ann Surg* 2008 Feb;247(2):320-6.
39. Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I, et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. *Crit Care Med* 2007 Jan;35(1):199-206.

40. Yuan HT, Tipping PG, Li XZ, Long DA, Woolf AS. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. *Kidney Int* 2002 Jun;61(6):2078-89.
41. Ganter MT, Cohen MJ, Brohi K, Chesebrough BB, Staudenmayer KL, Rahn P, et al. Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? *Ann Surg* 2008 Feb;247(2):320-6.
42. van der Heijden M, Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VW, Groeneveld AB. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. *Thorax* 2008 Oct;63(10):903-9.
43. Gallagher DC, Parikh SM, Balonov K, Miller A, Gautam S, Talmor D, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. *Shock* 2008 Jun;29(6):656-61.
44. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. *N Engl J Med* 1995 Aug 10;333(6):333-6.
45. Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie BW, Young EW, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. *Transplantation* 2002 Nov 15;74(9):1281-6.
46. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. *N Engl J Med* 1995 Aug 10;333(6):333-6.
47. van Der Hoeven JA, Molema G, Ter Horst GJ, Freund RL, Wiersema J, van SR, et al. Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. *Kidney Int* 2003 Nov;64(5):1874-82.
48. Koudstaal LG, 't Hart NA, van den Berg A., Olinga P, van GH, Ploeg RJ, et al. Brain death causes structural and inflammatory changes in donor intestine. *Transplant Proc* 2005 Jan;37(1):448-9.
49. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. *Transplantation* 1998 Jun 27;65(12):1533-42.
50. Weiss S, Kotsch K, Francuski M, Reutzel-Selke A, Mantouvalou L, Klemz R, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. *Am J Transplant* 2007 Jun;7(6):1584-93.
51. Nijboer WN, Schuur TA, van Der Hoeven JA, Fekken S, Wiersema-Buist J, Leuvenink HG, et al. Effect of brain death on gene expression and tissue activation in human donor kidneys. *Transplantation* 2004 Oct 15;78(7):978-86.
52. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. *Cancer Cell* 2004 Nov;6(5):507-16.
53. Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. *Circulation* 2003 Mar 11;107(9):1308-14.
54. Sullivan CC, Du L, Chu D, Cho AJ, Kido M, Wolf PL, et al. Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway. *Proc Natl Acad Sci U S A* 2003 Oct 14;100(21):12331-6.
55. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. *J Intern Med* 2005 Oct;258(4):336-43.
56. Mofarrah M, Nohu T, Qureshi S, Guillot L, Mayaki D, Hussain SN. Regulation of angiopoietin expression by bacterial lipopolysaccharide. *Am J Physiol Lung Cell Mol Physiol* 2008 May;294(5):L955-L963.
57. Kumpers P, van MM, David S, Molema G, Bijzet J, Lukasz A, et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. *Crit Care* 2009 May 5;13(3):R64.